{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:39:28Z","timestamp":1792622368672,"version":"4.5.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["advancesinanesthesia.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Anesthesia"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.aan.2026.06.003","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T11:22:39Z","timestamp":1784114559000},"page":"49-68","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Perioperative Management of Antihyperglycemic Medications"],"prefix":"10.1016","volume":"44","author":[{"given":"Christopher B.C.","family":"Koo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soyun Michelle","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manpreet S.","family":"Mundi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Pasternak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.aan.2026.06.003_bib1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2991\/jegh.k.191028.001","article-title":"Epidemiology of type 2 diabetes - global burden of disease and forecasted trends","volume":"10","author":"Khan","year":"2020","journal-title":"J Epidemiol Glob Health"},{"issue":"11","key":"10.1016\/j.aan.2026.06.003_bib2","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2025.5956","article-title":"Diagnosis and treatment of type 2 diabetes in adults: a review","volume":"334","author":"Kalyani","year":"2025","journal-title":"JAMA"},{"issue":"23","key":"10.1016\/j.aan.2026.06.003_bib4","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMsa2032271","article-title":"Trends in diabetes treatment and control in U.S. adults, 1999-2018","volume":"384","author":"Fang","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.aan.2026.06.003_bib5","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/jamasurg.2025.4706","article-title":"Preoperative hemoglobin A1C, glycemic status, and postoperative outcomes in general surgery","volume":"161","author":"Schaschinger","year":"2026","journal-title":"JAMA Surg"},{"issue":"1","key":"10.1016\/j.aan.2026.06.003_bib6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/SLA.0b013e31827b6bbc","article-title":"Importance of perioperative glycemic control in general surgery","volume":"257","author":"Kwon","year":"2013","journal-title":"Ann Surg"},{"issue":"16","key":"10.1016\/j.aan.2026.06.003_bib7","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1097\/BRS.0000000000004703","article-title":"Preoperative HbA1c and postoperative outcomes in spine surgery: a systematic review and meta-analysis","volume":"48","author":"Tao","year":"2023","journal-title":"Spine"},{"issue":"1","key":"10.1016\/j.aan.2026.06.003_bib8","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1017\/ice.2015.249","article-title":"Diabetes and risk of surgical site infection: a systematic review and meta-analysis","volume":"37","author":"Martin","year":"2016","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"4","key":"10.1016\/j.aan.2026.06.003_bib9","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jamcollsurg.2015.07.013","article-title":"Preoperative glycosylated hemoglobin and postoperative glucose together predict major complications after abdominal surgery","volume":"221","author":"Goodenough","year":"2015","journal-title":"J Am Coll Surg"},{"issue":"3","key":"10.1016\/j.aan.2026.06.003_bib10","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1213\/ANE.0000000000006791","article-title":"Society for ambulatory anesthesia updated consensus statement on perioperative blood glucose management in adult patients with diabetes mellitus undergoing ambulatory surgery","volume":"139","author":"Rajan","year":"2024","journal-title":"Anesth Analg"},{"issue":"6","key":"10.1016\/j.aan.2026.06.003_bib11","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.mayocp.2020.10.002","article-title":"Preoperative management of endocrine, hormonal, and urologic medications: society for perioperative assessment and quality improvement (SPAQI) consensus statement","volume":"96","author":"Pfeifer","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.aan.2026.06.003_bib12","unstructured":"Australian Diabetes Society. ADS-ANZCA Perioperative Diabetes and Hyperglycaemia Guidelines (Adults). 2 Nov. 2022."},{"key":"10.1016\/j.aan.2026.06.003_bib13","doi-asserted-by":"crossref","DOI":"10.1111\/anae.70181","article-title":"Peri-operative management of diabetes mellitus: a multidisciplinary consensus statement from the association of anaesthetists and the joint British diabetes societies for inpatient care group","author":"Levy","year":"2026","journal-title":"Anaesthesia"},{"issue":"Supplement_1","key":"10.1016\/j.aan.2026.06.003_bib14","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.2337\/dc26-S001","article-title":"Improving care and promoting health in populations: standards of care in diabetes\u20142026","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.aan.2026.06.003_bib15","article-title":"Perioperative glycaemic control for people with diabetes undergoing surgery","volume":"2023","author":"Bellon","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.aan.2026.06.003_bib16","series-title":"Perioperative care of people with diabetes undergoing surgery","year":"2024"},{"issue":"1","key":"10.1016\/j.aan.2026.06.003_bib17","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bja.2025.04.001","article-title":"Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: society for perioperative assessment and quality improvement (SPAQI) multidisciplinary consensus statement","volume":"135","author":"Oprea","year":"2025","journal-title":"Br J Anaesth"},{"issue":"13","key":"10.1016\/j.aan.2026.06.003_bib18","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1517\/14656566.2015.1070827","article-title":"Therapeutic potential of \u03b1-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review","volume":"16","author":"Joshi","year":"2015","journal-title":"Expert Opin Pharmacother"},{"issue":"18","key":"10.1016\/j.aan.2026.06.003_bib19","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1080\/14656566.2019.1672660","article-title":"Considerations when using alpha-glucosidase inhibitors in the treatment of type 2 diabetes","volume":"20","author":"Hedrington","year":"2019","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"10.1016\/j.aan.2026.06.003_bib20","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.bja.2023.02.039","article-title":"Current practice in the perioperative management of patients with diabetes mellitus: a narrative review","volume":"131","author":"Crowley","year":"2023","journal-title":"Br J Anaesth"},{"issue":"1","key":"10.1016\/j.aan.2026.06.003_bib21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.5694\/mja2.50239","article-title":"Metformin: time to review its role and safety in chronic kidney disease","volume":"211","author":"Tanner","year":"2019","journal-title":"Med J Aust"},{"issue":"2","key":"10.1016\/j.aan.2026.06.003_bib22","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.metabol.2015.10.014","article-title":"Metformin-associated lactic acidosis: current perspectives on causes and risk","volume":"65","author":"DeFronzo","year":"2016","journal-title":"Metabolism"},{"issue":"4","key":"10.1016\/j.aan.2026.06.003_bib23","article-title":"Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus","author":"Salpeter","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.aan.2026.06.003_bib24","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.2337\/dc14-0464","article-title":"Incidence of lactic acidosis in patients with type 2 diabetes with and without renal impairment treated with metformin: a retrospective cohort study","volume":"37","author":"Richy","year":"2014","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.aan.2026.06.003_bib25","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/dom.13118","article-title":"Peri-operative continuation of metformin does not improve glycaemic control in patients with type 2 diabetes: a randomized controlled trial","volume":"20","author":"Hulst","year":"2018","journal-title":"Diabetes Obes Metabol"},{"issue":"4","key":"10.1016\/j.aan.2026.06.003_bib26","doi-asserted-by":"crossref","first-page":"e277","DOI":"10.1016\/j.bja.2022.01.001","article-title":"Metformin and mortality after surgery: a systematic review and meta-analysis","volume":"128","author":"Jones","year":"2022","journal-title":"Br J Anaesth"},{"issue":"sup1","key":"10.1016\/j.aan.2026.06.003_bib27","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1517\/14740338.2014.944862","article-title":"DPP-4 inhibitors: pharmacological differences and their clinical implications","volume":"13","author":"Ceriello","year":"2014","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"10.1016\/j.aan.2026.06.003_bib28","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.2337\/db07-0136","article-title":"Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes","volume":"56","author":"Vella","year":"2007","journal-title":"Diabetes"},{"issue":"9982","key":"10.1016\/j.aan.2026.06.003_bib29","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1016\/S0140-6736(14)62225-X","article-title":"Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial","volume":"385","author":"Zannad","year":"2015","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.aan.2026.06.003_bib30","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.aan.2026.06.003_bib31","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000000691","article-title":"Type 2 diabetes mellitus and heart failure: a scientific statement from the American heart association and the heart failure society of America","volume":"140","author":"Dunlay","year":"2019","journal-title":"Circulation"},{"issue":"1\u20132","key":"10.1016\/j.aan.2026.06.003_bib32","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.2040-1124.2010.00022.x","article-title":"GIP and GLP-1, the two incretin hormones: similarities and differences","volume":"1","author":"Seino","year":"2010","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.aan.2026.06.003_bib33","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.2147\/DDDT.S506957","article-title":"A comprehensive review on the pharmacokinetics and drug\u2212drug interactions of approved GLP-1 receptor agonists and a dual GLP-1\/GIP receptor agonist","volume":"19","author":"Min","year":"2025","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.aan.2026.06.003_bib34","article-title":"Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists","volume":"15","author":"Liu","year":"2024","journal-title":"Front Endocrinol"},{"issue":"0","key":"10.1016\/j.aan.2026.06.003_bib35","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"0","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.aan.2026.06.003_bib36","series-title":"NCHS data briefs","first-page":"537","article-title":"GLP-1 injectable use among adults with diagnosed diabetes: united States, 2024. 2025 Aug","author":"Vahratian","year":"2024"},{"issue":"4","key":"10.1016\/j.aan.2026.06.003_bib37","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/anae.16541","volume":"80","author":"El-Boghdadly","year":"2025","journal-title":"Anaesthesia"},{"issue":"7","key":"10.1016\/j.aan.2026.06.003_bib38","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/anae.16306","article-title":"Glucagon-like peptide-1 receptor agonists: a narrative review of clinical pharmacology and implications for peri-operative practice","volume":"79","author":"Milder","year":"2024","journal-title":"Anaesthesia"},{"issue":"4","key":"10.1016\/j.aan.2026.06.003_bib39","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.aan.2026.06.003_bib40","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2024.0111","article-title":"Glucagon-like peptide-1 receptor agonist use and residual gastric content before anesthesia","volume":"159","author":"Sen","year":"2024","journal-title":"JAMA Surg"},{"issue":"8","key":"10.1016\/j.aan.2026.06.003_bib41","doi-asserted-by":"crossref","first-page":"5135","DOI":"10.1007\/s00464-025-11962-4","article-title":"Impact of GLP-1 receptor agonists on upper gastrointestinal endoscopy: an updated systematic review and meta-analysis","volume":"39","author":"Abdulraheem","year":"2025","journal-title":"Surg Endosc"},{"issue":"8","key":"10.1016\/j.aan.2026.06.003_bib42","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1111\/dom.15636","article-title":"Risks of peri and postoperative complications with glucagon-like peptide-1 receptor agonists","volume":"26","author":"Klonoff","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"10.1016\/j.aan.2026.06.003_bib43","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1111\/dom.15711","article-title":"No association between semaglutide and postoperative pneumonia in people with diabetes undergoing elective surgery","volume":"26","author":"Welk","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"19","key":"10.1016\/j.aan.2026.06.003_bib44","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1001\/jama.2024.5003","article-title":"Preoperative GLP-1 receptor agonist use and risk of postoperative respiratory complications","volume":"331","author":"Dixit","year":"2024","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.aan.2026.06.003_bib45","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/anae.16601","article-title":"Association between glucagon-like peptide-1 receptor agonist use and peri-operative pulmonary aspiration: a systematic review and meta-analysis","volume":"80","author":"Elkin","year":"2025","journal-title":"Anaesthesia"},{"issue":"3","key":"10.1016\/j.aan.2026.06.003_bib46","doi-asserted-by":"crossref","first-page":"e250081","DOI":"10.1001\/jamanetworkopen.2025.0081","article-title":"Postoperative aspiration pneumonia among adults using GLP-1 receptor agonists","volume":"8","author":"Chen","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.aan.2026.06.003_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.bjao.2024.100282","article-title":"Preoperative fasting and the risk of pulmonary aspiration\u2014A narrative review of historical concepts, physiological effects, and new perspectives","volume":"10","author":"R\u00fcggeberg","year":"2024","journal-title":"BJA Open"},{"issue":"11","key":"10.1016\/j.aan.2026.06.003_bib48","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1111\/anae.16117","article-title":"Pre-operative gastric ultrasound in patients at risk of pulmonary aspiration: a prospective observational cohort study","volume":"78","author":"Baettig","year":"2023","journal-title":"Anaesthesia"},{"key":"10.1016\/j.aan.2026.06.003_bib49","doi-asserted-by":"crossref","first-page":"111668","DOI":"10.1016\/j.jclinane.2024.111668","article-title":"Effect of various perioperative semaglutide interruption intervals on residual gastric content assessed by esophagogastroduodenoscopy: a retrospective single center observational study","volume":"99","author":"Santos","year":"2024","journal-title":"J Clin Anesth"},{"issue":"12","key":"10.1016\/j.aan.2026.06.003_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.soard.2024.08.033","article-title":"Multisociety clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period","volume":"20","author":"Kindel","year":"2024","journal-title":"Surg Obes Relat Dis"},{"issue":"5","key":"10.1016\/j.aan.2026.06.003_bib51","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1177\/0310057X251355288","article-title":"2025 ADS\/ANZCA\/GESA\/NACOS clinical practice recommendations on the peri-procedural use of GLP-1\/GIP receptor agonists","volume":"53","author":"Hocking","year":"2025","journal-title":"Anaesth Intensive Care"},{"issue":"12","key":"10.1016\/j.aan.2026.06.003_bib52","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1111\/anae.16454","article-title":"Relationship between residual gastric content and peri-operative semaglutide use assessed by gastric ultrasound: a prospective observational study","volume":"79","author":"Nersessian","year":"2024","journal-title":"Anaesthesia"},{"issue":"26","key":"10.1016\/j.aan.2026.06.003_bib53","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.3748\/wjg.v30.i26.3221","article-title":"Is it necessary to stop glucagon-like peptide-1 receptor agonists prior to endoscopic procedure? A retrospective study","volume":"30","author":"Ghazanfar","year":"2024","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.aan.2026.06.003_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103680","article-title":"Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis","volume":"90","author":"Tzang","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"Supplement 3","key":"10.1016\/j.aan.2026.06.003_bib55","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.2337\/diabetes.53.suppl_3.S151","article-title":"Kinetics-effect relations of insulin-releasing drugs in patients with type 2 diabetes: brief overview","volume":"53","author":"Melander","year":"2004","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.aan.2026.06.003_bib56","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/pds.4337","article-title":"Comparative risk of serious hypoglycemia with oral antidiabetic monotherapy: a retrospective cohort study","volume":"27","author":"Leonard","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"S2","key":"10.1016\/j.aan.2026.06.003_bib57","first-page":"S269","article-title":"Combined SGLT1 and SGLT2 inhibitors and their role in diabetes care","volume":"20","author":"Danne","year":"2018","journal-title":"Diabetes Technol Ther"},{"issue":"2","key":"10.1016\/j.aan.2026.06.003_bib58","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.aan.2026.06.003_bib59","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2023-003666","article-title":"Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors","volume":"11","author":"Chow","year":"2023","journal-title":"BMJ Open Diabetes Research and Care"},{"issue":"9","key":"10.1016\/j.aan.2026.06.003_bib60","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.eprac.2022.06.006","article-title":"Inpatient perioperative euglycemic diabetic ketoacidosis due to sodium-glucose cotransporter-2 inhibitors - lessons from a case series and strategies to decrease incidence","volume":"28","author":"Mehta","year":"2022","journal-title":"Endocr Pract"},{"issue":"6","key":"10.1016\/j.aan.2026.06.003_bib61","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1002\/cpt.3615","article-title":"Sodium-glucose cotransporter-2 inhibitors and diabetic-ketoacidosis in T2DM patients: an updated meta-analysis and a mendelian randomization analysis","volume":"117","author":"Wang","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.aan.2026.06.003_bib62","article-title":"Editorial: euglycemic ketoacidosis concerns in perioperative use of SGLT2 inhibitors: re-examining current recommendations","author":"Hwang","year":"2025","journal-title":"Anesthesia Patient Safety Foundation"},{"issue":"3","key":"10.1016\/j.aan.2026.06.003_bib63","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00540-023-03174-8","article-title":"Sodium-glucose cotransporter 2 inhibitor-associated perioperative ketoacidosis: a systematic review of case reports","volume":"37","author":"Seki","year":"2023","journal-title":"J Anesth"},{"issue":"1","key":"10.1016\/j.aan.2026.06.003_bib64","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc23-1163","article-title":"Euglycemic ketoacidosis in two patients without diabetes after introduction of sodium\u2013glucose cotransporter 2 inhibitor for heart failure with reduced ejection fraction","volume":"47","author":"Umapathysivam","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.aan.2026.06.003_bib65","article-title":"Sodium-glucose cotransporter-2 inhibitors in non-diabetic patients: is there a perioperative risk of euglycaemic ketoacidosis","author":"Ruste","year":"2023","journal-title":"Br J Anaesth"},{"issue":"13","key":"10.1016\/j.aan.2026.06.003_bib66","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1161\/CIRCULATIONAHA.123.065748","article-title":"Blinded withdrawal of long-term randomized treatment with empagliflozin or placebo in patients with heart failure","volume":"148","author":"Packer","year":"2023","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.aan.2026.06.003_bib67","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S2213-8587(20)30381-8","article-title":"Management of diabetes and hyperglycaemia in the hospital","volume":"9","author":"Pasquel","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1016\/j.aan.2026.06.003_bib68","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s00125-013-2856-6","article-title":"Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis","volume":"56","author":"Hirst","year":"2013","journal-title":"Diabetologia"},{"issue":"11","key":"10.1016\/j.aan.2026.06.003_bib69","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.2337\/dc17-0595","article-title":"Pharmacologic differences of sulfonylureas and the risk of adverse cardiovascular and hypoglycemic events","volume":"40","author":"Douros","year":"2017","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.aan.2026.06.003_bib70","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.2337\/dci22-0014","article-title":"Heart failure: an underappreciated complication of diabetes. A consensus report of the American diabetes association","volume":"45","author":"Pop-Busui","year":"2022","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.aan.2026.06.003_bib71","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.2337\/dc07-0717","article-title":"Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08)","volume":"30","author":"Erdmann","year":"2007","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.aan.2026.06.003_bib72","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1056\/NEJMra040832","article-title":"Insulin analogues","volume":"352","author":"Hirsch","year":"2005","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.aan.2026.06.003_bib73","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.bjae.2024.04.007","article-title":"Update on the perioperative management of diabetes mellitus","volume":"24","author":"Polderman","year":"2024","journal-title":"BJA Educ"}],"container-title":["Advances in Anesthesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0737614626000110?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0737614626000110?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:04:13Z","timestamp":1792620253000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0737614626000110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S0737614626000110"],"URL":"https:\/\/doi.org\/10.1016\/j.aan.2026.06.003","relation":{},"ISSN":["0737-6146"],"issn-type":[{"value":"0737-6146","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perioperative Management of Antihyperglycemic Medications","name":"articletitle","label":"Article Title"},{"value":"Advances in Anesthesia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aan.2026.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}